Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chu, Yeonjeong | - |
dc.contributor.author | Reddy, B. Raja Sekhara | - |
dc.contributor.author | Gajulapalli, V. Pratap Reddy | - |
dc.contributor.author | Babu, K. Sudhakar | - |
dc.contributor.author | Kim, Eunha | - |
dc.contributor.author | Lee, Sanghee | - |
dc.date.accessioned | 2024-01-19T16:00:59Z | - |
dc.date.available | 2024-01-19T16:00:59Z | - |
dc.date.created | 2021-09-02 | - |
dc.date.issued | 2020-12-15 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/117682 | - |
dc.description.abstract | Type I Interferon (IFN) signaling plays an important role in the immune defense system against virus infection and in the innate immune response, thus IFNs are widely used as anti-viral agents and treatment for immune disorder or cancer. However, there is a growing demand for novel small-molecule IFN inducer due to tolerance, toxicity, or short duration of action following direct administration of IFNs. In this study, we assessed arylpiperazine (ARP) as a new core skeleton of IFN inducer. To investigate structure-activity relationship, we designed and synthesized a series of ARP analogues and evaluated the ability to stimulate IFN response in THP-1 human monocyte cells. Compound 5i was identified as a potent type I IFN inducer as it significantly increased cytokine secretion and increased expression of various IFN-stimulating genes which are representative biomarkers of type I IFN pathway. Our results suggested a beneficial therapeutic potential of 5i as an anti-viral agent. | - |
dc.language | English | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.subject | MULTIPLE-SCLEROSIS | - |
dc.subject | HEPATITIS | - |
dc.subject | DISEASES | - |
dc.subject | GAMMA | - |
dc.subject | BETA | - |
dc.title | Design, synthesis, and biological evaluation of N-arylpiperazine derivatives as interferon inducers | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bmcl.2020.127613 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | Bioorganic & Medicinal Chemistry Letters, v.30, no.24 | - |
dc.citation.title | Bioorganic & Medicinal Chemistry Letters | - |
dc.citation.volume | 30 | - |
dc.citation.number | 24 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000595378800018 | - |
dc.identifier.scopusid | 2-s2.0-85094216931 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | MULTIPLE-SCLEROSIS | - |
dc.subject.keywordPlus | HEPATITIS | - |
dc.subject.keywordPlus | DISEASES | - |
dc.subject.keywordPlus | GAMMA | - |
dc.subject.keywordPlus | BETA | - |
dc.subject.keywordAuthor | Interferon inducer | - |
dc.subject.keywordAuthor | type I Interferon | - |
dc.subject.keywordAuthor | Arylpiperazine | - |
dc.subject.keywordAuthor | Anti-viral agent | - |
dc.subject.keywordAuthor | Innate immunity | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.